Cargando…

Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies

The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Rajbharan, Sukumaran, Siddharth, Zabka, Tanja S., Li, Jinze, Oldendorp, Amy, Morrow, Gary, Reyes, Arthur, Cheu, Melissa, Li, Jessica, Wallin, Jeffrey J., Tsai, Siao, Sun, Laura, Wang, Peiyin, Ellerman, Diego, Spiess, Christoph, Polson, Andy, Stefanich, Eric G., Kamath, Amrita V., Ovacik, Meric A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147001/
https://www.ncbi.nlm.nih.gov/pubmed/35631556
http://dx.doi.org/10.3390/pharmaceutics14050970
_version_ 1784716700792389632
author Yadav, Rajbharan
Sukumaran, Siddharth
Zabka, Tanja S.
Li, Jinze
Oldendorp, Amy
Morrow, Gary
Reyes, Arthur
Cheu, Melissa
Li, Jessica
Wallin, Jeffrey J.
Tsai, Siao
Sun, Laura
Wang, Peiyin
Ellerman, Diego
Spiess, Christoph
Polson, Andy
Stefanich, Eric G.
Kamath, Amrita V.
Ovacik, Meric A.
author_facet Yadav, Rajbharan
Sukumaran, Siddharth
Zabka, Tanja S.
Li, Jinze
Oldendorp, Amy
Morrow, Gary
Reyes, Arthur
Cheu, Melissa
Li, Jessica
Wallin, Jeffrey J.
Tsai, Siao
Sun, Laura
Wang, Peiyin
Ellerman, Diego
Spiess, Christoph
Polson, Andy
Stefanich, Eric G.
Kamath, Amrita V.
Ovacik, Meric A.
author_sort Yadav, Rajbharan
collection PubMed
description The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for preclinical characterization. To evaluate the impact of CD3 binding affinity on the TDB pharmacokinetics (PK), we utilized non-tumor-targeting bispecific anti-gD/CD3 antibodies composed of a low/high CD3 affinity arm along with a monospecific anti-gD arm as controls in monkeys and mice. An integrated PKPD model was developed to characterize PK and pharmacodynamics (PD). This study revealed the impact of CD3 binding affinity on anti-cyCD79b/CD3 PK. The surrogate anti-cyCD79b/CD3 TDB was highly effective in killing CD79b-expressing B cells and exhibited nonlinear PK in monkeys, consistent with target-mediated clearance. A dose-dependent decrease in B cell counts in peripheral blood was observed, as expected. Modeling indicated that anti-cyCD79b/CD3 TDB’s rapid and target-mediated clearance may be attributed to faster internalization of CD79b, in addition to enhanced CD3 binding. The model yielded unbiased and precise curve fits. These findings highlight the complex interaction between TDBs and their targets and may be applicable to the development of other biotherapeutics.
format Online
Article
Text
id pubmed-9147001
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91470012022-05-29 Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies Yadav, Rajbharan Sukumaran, Siddharth Zabka, Tanja S. Li, Jinze Oldendorp, Amy Morrow, Gary Reyes, Arthur Cheu, Melissa Li, Jessica Wallin, Jeffrey J. Tsai, Siao Sun, Laura Wang, Peiyin Ellerman, Diego Spiess, Christoph Polson, Andy Stefanich, Eric G. Kamath, Amrita V. Ovacik, Meric A. Pharmaceutics Article The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for preclinical characterization. To evaluate the impact of CD3 binding affinity on the TDB pharmacokinetics (PK), we utilized non-tumor-targeting bispecific anti-gD/CD3 antibodies composed of a low/high CD3 affinity arm along with a monospecific anti-gD arm as controls in monkeys and mice. An integrated PKPD model was developed to characterize PK and pharmacodynamics (PD). This study revealed the impact of CD3 binding affinity on anti-cyCD79b/CD3 PK. The surrogate anti-cyCD79b/CD3 TDB was highly effective in killing CD79b-expressing B cells and exhibited nonlinear PK in monkeys, consistent with target-mediated clearance. A dose-dependent decrease in B cell counts in peripheral blood was observed, as expected. Modeling indicated that anti-cyCD79b/CD3 TDB’s rapid and target-mediated clearance may be attributed to faster internalization of CD79b, in addition to enhanced CD3 binding. The model yielded unbiased and precise curve fits. These findings highlight the complex interaction between TDBs and their targets and may be applicable to the development of other biotherapeutics. MDPI 2022-04-30 /pmc/articles/PMC9147001/ /pubmed/35631556 http://dx.doi.org/10.3390/pharmaceutics14050970 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yadav, Rajbharan
Sukumaran, Siddharth
Zabka, Tanja S.
Li, Jinze
Oldendorp, Amy
Morrow, Gary
Reyes, Arthur
Cheu, Melissa
Li, Jessica
Wallin, Jeffrey J.
Tsai, Siao
Sun, Laura
Wang, Peiyin
Ellerman, Diego
Spiess, Christoph
Polson, Andy
Stefanich, Eric G.
Kamath, Amrita V.
Ovacik, Meric A.
Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
title Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
title_full Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
title_fullStr Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
title_full_unstemmed Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
title_short Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
title_sort nonclinical pharmacokinetics and pharmacodynamics characterization of anti-cd79b/cd3 t cell-dependent bispecific antibody using a surrogate molecule: a potential therapeutic agent for b cell malignancies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147001/
https://www.ncbi.nlm.nih.gov/pubmed/35631556
http://dx.doi.org/10.3390/pharmaceutics14050970
work_keys_str_mv AT yadavrajbharan nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT sukumaransiddharth nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT zabkatanjas nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT lijinze nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT oldendorpamy nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT morrowgary nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT reyesarthur nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT cheumelissa nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT lijessica nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT wallinjeffreyj nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT tsaisiao nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT sunlaura nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT wangpeiyin nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT ellermandiego nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT spiesschristoph nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT polsonandy nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT stefanichericg nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT kamathamritav nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies
AT ovacikmerica nonclinicalpharmacokineticsandpharmacodynamicscharacterizationofanticd79bcd3tcelldependentbispecificantibodyusingasurrogatemoleculeapotentialtherapeuticagentforbcellmalignancies